Cypress Wealth Advisors LLC decreased its position in Bristol-Myers Squibb Company (NYSE:BMY) by 36.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,149 shares of the biopharmaceutical company’s stock after selling 12,502 shares during the quarter. Bristol-Myers Squibb comprises approximately 1.4% of Cypress Wealth Advisors LLC’s holdings, making the stock its 18th largest position. Cypress Wealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $1,234,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Tradewinds Capital Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 34.6% during the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 500 shares during the last quarter. American National Bank lifted its holdings in shares of Bristol-Myers Squibb by 11.7% during the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 225 shares during the last quarter. Blue Chip Partners Inc. lifted its holdings in shares of Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 15 shares during the last quarter. BDO Wealth Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb during the second quarter valued at $123,000. Finally, Acrospire Investment Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 633.3% during the second quarter. Acrospire Investment Management LLC now owns 2,200 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 1,900 shares during the last quarter. Institutional investors and hedge funds own 69.82% of the company’s stock.
Bristol-Myers Squibb Company (BMY) opened at $63.28 on Wednesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10. The firm has a market capitalization of $103,144.84, a PE ratio of 21.29, a price-to-earnings-growth ratio of 2.39 and a beta of 1.18.
The company also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be given a $0.40 dividend. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.53%. The ex-dividend date is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 61.42%.
BMY has been the subject of several research analyst reports. Barclays increased their price objective on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Friday, October 13th. Jefferies Group downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price objective for the company. in a research note on Monday, October 16th. BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 12th. Leerink Swann increased their price objective on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research note on Monday, October 23rd. Finally, Citigroup increased their price objective on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $64.93.
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the transaction, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.23% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://weekherald.com/2017/12/13/bristol-myers-squibb-company-bmy-shares-sold-by-cypress-wealth-advisors-llc.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.